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Abstract: Recently, we have described a simple protocol to obtain an enriched culture of 
adult stem cells organized in neurospheres from two post-natal tissues: skin and adipose 
tissue. Due to their possible application in neuronal tissue regeneration, here we tested  
two kinds of scaffold well known in tissue engineering application: hyaluronan based 
membranes and fibrin-glue meshes. Neurospheres from skin and adipose tissue were 
seeded onto two scaffold types: hyaluronan based membrane and fibrin-glue meshes. 
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Neurospheres were then induced to acquire a glial and neuronal-like phenotype. Gene 
expression, morphological feature and chromosomal imbalance (kariotype) were analyzed 
and compared.  Adipose and skin derived neurospheres are able to grow well and to 
differentiate into glial/neuron cells without any chromosomal imbalance in both scaffolds. 
Adult cells are able to express typical cell surface markers such as S100; GFAP; nestin; 
βIII tubulin; CNPase. In summary, we have demonstrated that neurospheres isolated from 
skin and adipose tissues are able to differentiate in glial/neuron-like cells, without any 
chromosomal imbalance in two scaffold types, useful for tissue engineering application: 
hyaluronan based membrane and fibrin-glue meshes. 
Keywords:  adipose  derived stem cells;  skin;  adipose tissue;  stem cells;  
Schwann cell; karyotypes 
 
1. Introduction 
Interest about novel stem cell-based therapies has exponentially been increasing over the past years, 
not only in the scientific community but also within the society. Indeed, stem cells seem to give the 
best chance for human tissue engineering, and particularly, mesenchymal stem cells (MSCs) represent 
a great tool in regenerative medicine because of their ability to differentiate into a variety of 
specialized cells in addition to their immuno-privileged characteristics [1,2]. 
Mesenchymal stem cells are adherent stromal cells able to self-renew and differentiate into a wide 
variety of cells and tissues. Mesenchymal stem cells can be isolated from different sources: amnion, 
placenta, bone marrow, umbilical cord and cord blood, adipose tissue and dental pulp are the most 
common ones; moreover, these cells are available in virtually all post-natal tissues. As adult stem cells, 
mesenchymal stem cells have not the tumorigenic potential as their embryonic correlatives and possess 
other unique characteristics such as their almost null immunogenicity. Moreover, these cells seem to 
be immunosuppressive in vitro [3,4]. 
Mesenchymal stem cells can differentiate  into non-mesenchymal lineages as a result of their   
great plasticity. 
While MSCs were initially defined by their ability to differentiate into cells of mesodermal origin, 
recent studies have provided support for their capacity to differentiate into cells from all three germ 
layers [5]. In addition, MSCs have other characteristics making them attractive modalities for treating 
human disease. These cells are described as MHC II negative cells, lacking co-stimulatory molecules 
such as CD40, CD80 and CD86, which permit allogenic transplantation without immunosuppression [6]. 
Furthermore, they can be easily isolated from an autologous source, enabling easy accessibility for 
therapeutic intent. MSCs can provide therapeutic benefit through the secretion of specific cytokines,  
ex vivo genetic modification and direct cell-cell contact. As such, these cells have been studied for 
their use in diverse diseases ranging from genetic disorders to tissue ischemia [7]. 
In this context, the ability to generate Schwann cells and their precursors from adult non-neural 
tissues such as bone marrow, adipose tissue and skin is of significant clinical interest [8]. Schwann 
cells can provide beneficial therapeutic effects in both the peripheral and central nervous systems by Int. J. Mol. Sci. 2011, 12  6751 
 
 
remyelination, provision of trophic support, and a role in promoting axon regeneration [9]. A number 
of recent reports have suggested that cells with a glial phenotype can be generated from stem cells 
derived from both bone marrow and skin [10–12]. However, the identity of the original cells that give 
rise to putative Schwann cells remains poorly defined. In both cases, it has been proposed that 
Schwann cells are generated from precursors within these tissues. In the case of bone marrow and 
adipose tissue, this differentiation started from MSC; in the case of skin, Schwann cell differentiation 
has been reported from skin-derived precursor cells (SKPs). SKPs are defined as multipotent precursor 
cells that can grow as self-renewing precursors under substrate-free conditions in media specialized for 
neural precursor propagation [13,14]. SKPs have also been shown to possess mesenchymal as well as 
neuroglial potential [15]. 
In light of such considerations, one possible clinical application of this ability is undoubtedly the  
in vitro or in vivo studies of the mechanism for the treatment of neurodegenerative states, such as 
Parkinson’s disease, Hungtinton’s disease, multiple sclerosis and Alzheimer’s disease [16–18]. 
In order to reach these goals, other necessary strategies, such as tissue engineering and regenerative 
medicine, should be combined with stem cell biology. Indeed the ability of the scaffolds to support 3D 
growth, differentiation or cell-release in situ are well known [19,20]. 
Tissue Engineering and regenerative medicine aim to investigate the deposition, growth and 
remodeling of tissues by drawing together approaches from a range of disciplines [21]. 
Recent developments in the multidisciplinary field of tissue engineering have yielded many novel 
tissue replacements and implementation strategies. Scientific advances in biomaterials, stem cell 
isolation, growth and differentiation factors and biomimetic environments have created unique 
opportunities to fabricate tissues in the laboratory. One of the major challenges now facing tissue 
engineering is to optimize 3D functional recovery, a factor dependent on 3D structural complexity, as 
well as the biomechanical and functional stability of the laboratory-grown tissues destined for 
transplantation [22]. 
A variety of synthetic and naturally derived materials may be used for tissue engineered scaffolds. 
Synthetic materials include poly(ethylene oxide), poly(vinyl alcohol), whereas representative naturally 
derived polymers include agarose, alginate, chitosan, collagen, fibrin, gelatin, and hyaluronic acid [23]. 
Selection or synthesis of the appropriate hydrogel scaffold materials is governed by the physical 
property, the mass transport property, and the biological interaction requirements of each specific 
application. These properties or design variables are specified by the intended scaffold application and 
environment into which the scaffold will be placed [24–27]. 
In light of these considerations, our lab recently merged its great experience in biomaterials with its 
expertise in tissue engineering to obtain the in vitro commitment of adult mesenchymal stem cells—
skin and adipose tissue derived—into a neuronal phenotype [28,29]. 
With our previous results [14,15], we established a protocol for the isolation and amplification in vitro 
of a population of adult neuronal stem cells from two tissues: skin and adipose tissue. 
We can summarize that the principal culture requirements for the successful formation of 
neurospheres in vitro from either skin or adipose tissue are the following: (1) cells isolated from the 
tissue must be cultured without coating chamber slides; (2) the proliferative medium must contain 
serum; and (3) both EGF and FGF2 must be added to the media. Int. J. Mol. Sci. 2011, 12  6752 
 
 
With this protocol, skin derived stem cells, termed skin-derived precursors (SKPs), were isolated 
and expanded from human skin-adipose tissue and differentiated into neural and mesodermal progeny, 
including cell types that are never found in skin or in adipose tissue, such as neurons. 
With a very simple protocol, putative adult human neural crest precursors, firstly  in form of 
proliferative neurospheres, then involving only the use of two similar mitogens (FGF2 and EGF) in 
two weeks we were able to isolate and expand populations of adult human CNS precursors and in cells 
with a neural-glial like morphology. 
Surprisingly, the amount and the neurological properties of these stem cells are comparable. The 
encouraging results obtained in monolayer cultures, drove us to investigate cell commitment in a 3D 
system. In order to detect the best material, we compared two scaffolds: hyaluronan based and fibrin 
based scaffolds. Genetical, biochemical, molecular biology and morphological approaches have been 
used to better characterize the influence of the nature of the biomaterial on stem cells. 
2. Results and Discussion 
2.1. Biomaterials 
2.1.1. Hyaluronan 
Biomaterials used in the present study were derived from the total esterification of hyaluronan 
(synthesized from 80–200 kDa sodium hyaluronate) with benzyl alcohol, referred to as HYAFF-11™. 
The final product is an uncross-linked linear polymer with an undetermined molecular weight; it is 
insoluble in aqueous solution yet spontaneously hydrolyzes over time, releasing benzyl alcohol and 
hyaluronan. HYAFF-11™ was used to create non-woven meshes (NW) (50 μm-thick fibers; specific 
weight of 100 g/m
2). These devices were obtained from Fidia Advanced Biopolymers (FAB, Abano 
Terme, Italy). 
2.1.2. Fibrin Glue 
Fibrin glue is a synthetic substance made to create in vitro a fibrin clot. It is based by fibrinogen and 
thrombin that are injected through one head into the site of a fibrin tear. Thrombin acts as an enzyme 
and converts the fibrogen into fibrin between 10 and 60 s. These devices were obtained from Baxter 
(Baxter AG, Vienna, Austria). 
2.2. Cell Cultures 
Skin biopsies and adipose tissue samples were obtained during abdominoplastic procedures from 
the abdominal region of a same set of seven patients (aged 35–58) who had given written consent. 
Cell extraction was performed according to previously published protocols for skin [11] and 
adipose tissue [12]. Briefly, the full-thickness skin biopsies (3 cm × 1 cm) were accurately cleared of 
the subcutaneous tissue and cut into 1 mm  ×  1 mm pieces. These were suspended in DMEM 
(Biochrom AG) and Whartington’s collagenase (Sigma) 80 U for overnight digestion. Adipose tissue 
was collected and cut into small pieces, suspended in DMEM with collagenase type 2 (Sigma) for  
90 min in slow agitation. After centrifugation for 5 min at 1000 rpm the supernatant was removed, the Int. J. Mol. Sci. 2011, 12  6753 
 
 
pellet was resuspended with a Pasteur pipette and the suspension was passed through a 70-µm cell
 
strainer (BD Biosciences, Mississauga, Ontario, Canada). The strained cell suspension was 
centrifuged, resuspended in proliferating medium (DMEM-HAM’s F12 (3:1), penicillin/streptomycin 
1%, EGF (20 ng/μL), FGF (40 ng/μL), FBS 10%) after removal of the supernatant and transferred to a 
25-cm
2 tissue culture flask (BD Biosciences). Cells were cultured at 37°C with 5% CO2 atmosphere.  
Proliferative  Medium:  DMEM-HAM’s F12,  3:1, penicillin/streptomycin 1%, EGF (1000×),  
FGF (100×), FBS (10%). 
Neuronal  Differentiative  Medium:  DMEM-F12,  3:1, 1% FBS, 2% b27 serum free supplement,   
10 μg/mL NGF, antibiotics [30]. 
Glial Differentiative Medium: DMEM-F12, 3:1, containing 1% FBS plus 1% N2 supplement, 4 µM 
forskolin,
 and 10 ng/mL heregulin β [31]. 
Non Differentiative Medium: Non hematopoietic (NH) stem cell expansion media (Miltenyi Biotec, 
Bergish Gladbach, Germany). 
2.3. Morphological Analysis 
Cultures were layered over glass slides, fixed with absolute acetone for 10 min at room temperature 
and cryopreserved at −20 °C until use. S100; GFAP; nestin; bIII tubulin; CNPase were visualized with 
immunofluorescence. Briefly, after non-specific antigen sites were saturated with 1/20 rabbit serum  
in 0.05 M maleate TRIZMA (Sigma; pH 7.6) for 20 s, 1/100 mouse anti-human S100 (Sigma) was 
added to the samples. After incubation, immunofluorescence staining was performed by means of 
fluorescein secondary antibody [32–35]. As negative control, reactions without primary antibody were 
used. No background in any sample has been revealed. Stem cells cultured in non differentiative 
medium have been used as negative control too. 
2.4. Morphological Analysis 
Cultures were layered over glass slides, fixed with absolute acetone for 10 min at room temperature 
and cryopreserved at −20 °C until use. S100; GFAP; nestin; bIII tubulin; CNPase were visualized with 
immunofluorescence. Briefly, after non-specific antigen sites were saturated with 1/20 rabbit serum in 
0.05 M maleate TRIZMA (Sigma; pH 7.6) for 20 s, 1/100 mouse anti-human S100 (Sigma) was added 
to the samples. After incubation, immunofluorescence staining was performed by means of fluorescein 
secondary antibody [17–19]. 
2.5. SEM 
Scaffolds were fixed, postfixed, dehydrated, and sputter coated with gold as standard protocols. 
Samples were examined using a Philips XL-40 scanning electron microscope (FEI, Eindhoven,   
The Netherlands). Int. J. Mol. Sci. 2011, 12  6754 
 
 
2.6. Cytogenetic Analysis 
At p3 cells were exposed to colchicines (Sigma Chemicals, St. Louis, MO, USA) for 6 h, detached 
with trypsin (Lonza, Milano, Italy), washed with phosphate-buffered saline (Lonza, Milano, Italy), 
subjected to sodium citrate 1% for 15 min at 37 °C, and  fixed and spread according to standard 
procedures. Metaphases of cells were Q-banded and karyotyped in accordance with the international 
System for Human Cytogenetic Nomenclature recommendations. Twenty-five metaphases were 
analyzed for three expansions. 
2.7. MTT Test 
MTT-based (thiazolyl blue) cytotoxicity test was performed as described in Denizot and Lang [35], 
with minor modifications. The test is based on mitochondria viability, i.e., only functional mitochondria 
can oxidize an MTT solution, giving a typical blue-violet end product. This assay is an indirect method 
to assess cell growth and proliferation since the optical density (OD) value can be correlated to the cell 
number. All samples were examined after 3, 7 and 14 days of culture. 
2.8. Statistical Analysis 
The one-way analysis of variance (Anova test) was used for data analyses. Repeat measurement 
analysis of variance (Re-ANOVA) and paired t tests were used to determine if there were significant 
changes (p < 0.05). * p < 0.05; ** p < 0.01; *** p < 0.001: Repeatability was calculated as the standard 
deviation of the difference between measurements. 
3. Experimental Section 
3.1. Chromosome Stability 
Chromosome stability of cell cultures has been detected by means of the karyotipe analyses. The 
karyotype describes the number of chromosomes, and what they look like under a light microscope. 
The chromosomes are depicted (by rearranging a microphotograph) in a standard format known as a 
karyogram: in pairs, ordered by size and position of centromere for chromosomes of the same size. 
The normal human karyotype contains 22 pairs of autosomal chromosomes and one pair of sex 
chromosomes. Normal karyotypes for females contain two X chromosomes. In our experiments all the 
adipose derived stem cells are 46-XX since they derived from female abdominoplastic adipose tissue 
part, males have both an X and a Y chromosome and are denoted 46-XY. Whereas skin derived stem 
cells used in our experiments have an XY set of sexual chromosomes since they derived from male 
abdominoplastic dermal tissue parts. Any variation from the standard karyotype may lead to 
developmental abnormalities. 
Karyotypes of skin-derived precursors and adipose derived stem cells have been performed during 
the main phases of the protocol: 
Two days after the digestion of the tissues (Figure 1a), with the aim to establish the presence of any 
chromosome imbalance in the original status of the cells. Int. J. Mol. Sci. 2011, 12  6755 
 
 
Fourteen days after a treatment in proliferative medium (Figure 1b), with the aim to verify if the 
factors present in the proliferative medium were able to induce some alterations in the normal sets  
of chromosomes. 
Fourteen days after a treatment in differentiative medium (Figure 1c for the neuronal medium and 
Figure 1d for the Glial one), in order to verify if the new factors associated to the long term culture  
(28 days after the digestion) were able to induce some chromosomal alterations. 
Figure 1. Karyotypes of skin-derived precursors (SKPs) and adipose derived stem cells 
(ADSc) have been performed during the principal phase of the protocol: 2 days after the 
digestion of the tissue; 14 days after a treatment in proliferative medium; 14 days after a 
treatment in differentiative medium (Figure  1c for the neuronal and Figure  1d for the   
Glial one). 
 
As reported in all the figures, cells cultured in all the conditions tested give rise to normal 
karyotypes. No chromosomal imbalances such as trysomies or monosomies in chromosome number 
are evident, nor are translocation/deletion/duplication on chromosome structures present. 
3.2. Morphological Features in Monolayer Conditions 
After 14 days of culture in proliferative medium, skin-derived precursors and adipose derived stem 
cells have been treated with the specific differentiative medium. Int. J. Mol. Sci. 2011, 12  6756 
 
 
Markers for both neuronal and Schwann cells have been detected by immuno-staining in all cell 
types with the aim to test the correct commitment. 
In Figure 2, histological detection for the markers associated to a neuronal phenotype is reported. 
Figure 2. Immunofluorescence stainings to detect Vimentin, nestin, βIII tubulin on skin 
and adipose tissue-derived stem cells, in presence of neuronal differentiative medium. 
 
Vimentin (57 kDa) is the most ubiquitous intermediate filament protein and the first to be expressed 
during cell differentiation. Vimentin is present in a wide variety of mesenchymal cell types and in 
many cells from the neural crest. The positive staining for vimentin in both skin-derived precursors 
and adipose derived stem confirms their staminal state. 
The second protein whose expression is related to a neuronal phenotype is nestin. Nestin, a type VI 
IF protein, is a protein marker for neural stem cells since it is mostly expressed in nerve cells where it 
is implicated in the radial growth of the axon. Nestin is expressed in dividing cells during the early 
stages of development in the central  nervous  system. Upon differentiation, nestin becomes   
down-regulated and is replaced by tissue-specific IF proteins; in our monolayer cell cultures, both  
skin-derived precursors and adipose derived stem cells (Figure 2, second line) in presence of neuronal 
medium express nestin. During gliogenesis, nestin is replaced by IF, such as glial fibrillary acidic 
protein (GFAP). In our cultures, indeed, no cells express GFAP if cultured with neuronal medium 
(data not shown).  
The last protein tested for the validation of a neuronal phenotype is βIII tubulin, a protein abundant 
in the central and peripheral nervous systems (CNS and PNS) where it is prominently expressed   Int. J. Mol. Sci. 2011, 12  6757 
 
 
during fetal and post-natal development. Also in this case, all the cells show a good expression of this 
neuronal protein. 
Protein expression pattern during cultures in Glial cells medium is reported in Figure 3. Also for 
this treatment vimentin has been selected as a marker for stem cells. As reported in the first line, also 
in this case both cell types are positive. The co-expression of vimentin with GFAP; is typical of glial 
cells; an event that is well depicted in the fourth line of Figure 3. 
Figure 3. Immunofluorescence stainings to detect Vimentin, S100; CNP; nestin; GFAPase 
on skin and adipose tissue-derived stem cells in presence of glial differentiative medium. 
 
Vimentin is frequently included in the so-called primary panel (together with CD45, cytokeratin, 
and S-100 protein). In our panel we included the detection of S100, a calcium binding protein normally 
present in cells derived from the neural crest (Schwann cells and glial cells), in mesenchymal derived 
cells such as chondrocytes, adipocytes, and in dendritic cells. In line 2 of Figure 3, it is evident that 
both skin-derived precursors and adipose derived stem cells express S100 as confirmed by the red 
fluorescent staining. Int. J. Mol. Sci. 2011, 12  6758 
 
 
Nestin  and  CNPase:CNPase  (2′,3′-Cyclic Nucleotide 3′-Phosphodiesterase) is expressed at high 
levels by oligodendrocytes in the CNS and by Schwann cells in the peripheral nervous system (PNS), 
and it is virtually absent in other cell types. Its co-expression with nestin confirms the commitment of 
skin-derived precursors and adipose derived stem cells into a correct phenotype. 
3.3. Proliferation on 3D Cultures 
After induction of neurosphere formations in monolayer conditions, cells have been seeded into 
hyaluronan and fibrin based scaffolds. Proliferation ability of cells differentiated has been evaluated by 
means of an MTT test. As reported in Figure 4, the proliferation ability of the cells in both materials, 
grown in presence of proliferative medium, is evident. When cells are cultivated in differentiative 
medium (for glial or for neuro one) the rate decreases. Indeed, in this case, a selection of cells occurs 
(only neursphere are able to survive) and the cells acquire a well defined phenotype. Interestingly, no 
significant difference is evident between the scaffolds. 
Figure 4. Proliferation test (by means of MTT) of adipose derived stem cells and skin 
derived stem cells into hyaluronan (white bars) and fibrin glue (black bars) after 14 days in 
differentiative medium. The one-way analysis of variance (Anova test) was used for data 
analyses. Repeat measurement analysis of variance (Re-ANOVA) and paired t tests were 
used to determine if there were significant changes (p < 0.05). * p < 0,05; ** p < 0.01;  
*** p < 0.001: Repeatability was calculated as the standard deviation of the difference 
between measurements. 
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3.4. Gene Expression on 3D Cultures 
Commitment of adult stem cells into 3D scaffolds has been tested by means of gene expression 
analyses. Expression of markers for neural phenotypes such as vimentin, nestin, βIII tubulin and for 
glial commitment such as vimentin, S100, nestin, CNPase, GFAP, has been detected after 14 days of 
3D cultures in both scaffolds. As controls, adipose derived stem cells and skin derived stem cells 
cultured with no differentiative medium have  been used. In Figure  5,  expression of markers  in 
presence of differentiative medium,  compared with the expression in no differetiative medium, 
are reported.  
Figure 5. Gene expression analyses of adipose and skin derived stem cells after 14 days of 
culture in differentiative medium into hyaluronan (white bars) and into fibrin glue   
(black bars) based scaffolds. The one-way analysis of variance (Anova test) was used for 
data analyses. Repeat measurement analysis of variance (Re-ANOVA) and paired t tests 
were used to determine if there were significant changes (p < 0.05). * p < 0.05; ** p < 0.01; 
*** p < 0.001: Repeatability was calculated as the standard deviation of the difference 
between measurements. 
 
Results obtained confirm that in both scaffolds the correct commitment occurred. Expression of 
specific markers is indeed always detectable in hyaluronan or in fibrin glue based scaffolds and no 
significant difference between the biomaterials is evident. Int. J. Mol. Sci. 2011, 12  6760 
 
 
3.5. Electron Microscopy Analyses 
Skin-derived precursors and adipose derived stem cells have been cultured in scaffolds based on 
fibrin glue and hyaluronic acid. 
The thickness and the material of the materials did not allow the immunohistochemical staining 
previously obtained. For this reason we performed the morphological evaluation with SEM. 
Figure 6 reports SEM analyses of both skin-derived precursors and adipose derived stem cells 
treated with neuronal and Schwann cell medium on fibrin glue and hyaluronic acid based scaffolds. 
Figure 6.  SEM  analyses of skin and adipose tissue-derived stem cells in presence of 
glial/neuronal differentiative medium in hyaluronan/fibrin glue based scaffolds. 
 
The first panel is related to the phenotype acquired by the cells in presence of Glial cell 
differentiative medium. Skin-derived precursors and adipose derived stem cells show a classical shape Int. J. Mol. Sci. 2011, 12  6761 
 
 
with a triangular central group and typical somata and two or more pronounced dendrite or axon-like 
processes on fibrin glue. This phenotype is present also when cells are cultured in hyaluronan based 
scaffold. In this case adipose derived stem cells assume a flat and large conformation. 
When cells are cultured in presence of neuronal medium it is possible to conclude with the same 
observations: both skin-derived precursors and adipose derived stem cells are able to grow in both 
scaffolds acquiring the correct phenotype. Notably in hyaluronan scaffolds, cells may acquire a more 
fibroblastic-like feature reaching confluence in a few days. 
4. Discussion 
At present, great progress and breakthroughs have been achieved in stem cell-based therapies for 
neurodegenerative disorders. However, the development of stem cell-based therapies is still at an early 
stage. Many basic issues remain to be resolved. Although embryonic stem cells seem to have an 
unrestricted potential to differentiate towards neuroectodermal phenotypes, the differentiation in vitro 
is extremely random. Embryonic stem cells can give rise to teratomas and immune rejection response 
after transplantation. The risk of teratoma from embryonic stem cells, as well as the consequences of 
introducing new genes in stem cell-derived neurons, should be carefully evaluated [20]. An alternative 
source is neural stem cells for which the isolation process is standardized. Neuronal stem cells can 
differentiate into all of the major neural cell types in vivo and in vitro. When transplanted into the brain 
they are able to survive, migrate and integrate in a functionally active way. Stem cells isolated from 
adult brain as neurospheres generate fewer neurons than those isolated from embryonic or fetal brain, 
both in transplantation cases and in differentiating conditions in vitro [36,37]. Recently, great scientific 
success has been obtained from mesenchymal stem cells, isolated from different adult tissues.  
While embryonic stem cells and neuronal stem cells have great potential, mesenchymal stem cells 
also provide hopeful possibilities for clinical application, since they can be efficiently expanded   
in vitro and it is possible to acquire a therapeutic scale of induced cells. In addition, transplantation of 
mesenchymal stem cells-derived cells should pose fewer ethical problems by preventing stem cell 
controversy, since bone marrow transplantation has already been widely performed. Thus, from the 
point of view of the cell-based therapy, it is desirable to develop a systematic induction system to obtain 
large amounts of useful cells. Indeed, practical application to human degenerative diseases depends on 
the ability to control their differentiation into functional cells with high efficiency and purity. 
Recently we have demonstrated [14,15] that we are able to induce the in vitro commitment into a 
glial and neuronal like phenotype of adult stem cells derived from adipose tissue and skin. 
Due to these encouraging results, in the present work we translated our experience from a 
monolayer condition into 3D conditions, a more physiological environment. Firstly we checked the 
safety of our differentiation methods performing a detailed genomic analysis (by means of caryotiping) 
of cultures throughout  all the in vitro  steps (Figure  1). The absence of any structural alteration 
confirmed the safety to differentiate mesenchymal stem cells. 
The second step has been represented by the immunostaining of specific markers for neuronal and 
glial commitment (Figures 2 and 3). The expression and the morphology of the cells confirmed the 
correct phenotype was used. Int. J. Mol. Sci. 2011, 12  6762 
 
 
At this stage, we seeded the neuspheres into the two selected scaffolds: hyaluronan and fibrin glued 
based meshes. We then performed the proliferation test (Figure 4) to test the biocompatibility of the 
scaffolds and gene expression to test the commitment (Figure 5) of the cells. As it has been well 
evidenced, the scaffolds also support the growth and the differentiation process. The gene expression is 
clear, as reported in Figure 5, as all the specific markers have been detected. Finally, morphological 
features, such as the distribution into the scaffolds, have been analyzed with electron microscopy. 
Figure 6 reports on cell distribution and the morphological features of the cells in the two scaffolds. 
5. Conclusion 
In the present work, we showed the high ratio and specific induction of glial cells and neurons from 
adult stem cells derived from skin and adipose tissues. Moreover, we thoroughly checked the safety of 
our protocols. 
In conclusion, with classical tissue engineering techniques,  we tested two scaffolds based on 
hyaluronan and fibrin glue in order to confirm if the neuronal and glial commitment of the 
mesenchymal stem cells derived from adipoe tissue and skin could be feasible. 
The encouraging results clearly  showing morphological features related to a neuronal and   
glial-like phenotype, impel us to transfer our 3D cultures to an in vivo model. 
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